UK Could Block Activist Plans To Shake Up GSK

New Law Allows Intervention

GlaxoSmithKline is under attack from an activist investor, but as a key UK company, the government could use new powers to block any deals “not in the national interest”.

GSK_HQ

The UK government is worried about a bid by an activist investor to shake up GlaxoSmithKline, and could make use of new powers to protect companies that are seen as vital to the nation’s interests.

Alongside AstraZenenca, GSK is one of UK’s two big pharma companies, employing 13,000 people in the country and investing around...

More from Business

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?